a16z Crypto partner: DAOs will open up a new design space under regulatory clarity and AI agents
According to ChainCatcher, Ali Yahya, General Partner at a16z Crypto, stated in an article that during the last crypto era, DAOs (Decentralized Autonomous Organizations) were undoubtedly a failed experiment, but this may have been simply due to bad timing.
Ali Yahya admitted that over the past 10 years, the industry has painfully rediscovered that “direct democracy is a bad idea,” as no ordinary user is willing to wake up early to decide on risk parameters or protocol upgrades. He emphasized that as regulatory environments change, the industry will regain the legal space to experiment and explore representative democracy, bicameral systems, or hybrid architectures of permissioned and permissionless models; at the same time, AI agents can fill many management roles that humans are unwilling to take on, allowing DAOs to become truly “autonomous.” The design space for a new generation of DAOs, as software, will be limitless.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BNP Paribas gives Microsoft (MSFT.US) a "Buy" rating: Azure price increases will be gradually implemented after contract renewals, and a deal with SpaceX may be announced soon.
BNP Paribas has rated Microsoft as "Buy" with a target price of $549.
Iranian President will head to New York for UN meeting
"Big Short" Burry opens a position in QXO (QXO.US), betting on building products integration and undervaluation; stock price rises over 7%
Investor Michael Burry disclosed that he has purchased common and preferred shares of QXO (QXO.US), a building products company, citing its integration strategy and the currently depressed stock price. The stock surged 7.2% on Monday.
700,000 new elderly patients join, Eli Lilly (LLY.US) dominates 70%: The first Medicare weight loss drug coverage report released
Dave Ricks, CEO of Eli Lilly (LLY.US), said in an interview on Monday that since Medicare began coverage for obesity drugs in July, 700,000 new elderly patients have started using GLP-1 medications.
